BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Expression and secretion of CXCL12 are enhanced in autosomal dominant polycystic kidney disease

  • Kim, Hyunho (Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital) ;
  • Sung, Jinmo (Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital) ;
  • Kim, Hyunsuk (Internal Medicine, Hallym University Medical Center, Chuncheon Sacred Heart Hospital) ;
  • Ryu, Hyunjin (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Hayne Cho (Department of Internal Medicine, Hallym University Medical Center, Kangnam Sacred Heart Hospital) ;
  • Oh, Yun Kyu (Department of Internal Medicine, Seoul National University Boramae Medical Center) ;
  • Lee, Hyun-Seob (Genomics Core Facility, Department of Transdisciplinary Research and Collaboration, Biomedical Research Institute, Seoul National University Hospital) ;
  • Oh, Kook-Hwan (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Ahn, Curie (Department of Internal Medicine, Seoul National University College of Medicine)
  • Received : 2019.04.17
  • Accepted : 2019.05.23
  • Published : 2019.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), one of the most common human monogenic diseases (frequency of 1/1000-1/400), is characterized by numerous fluid-filled renal cysts (RCs). Inactivation of the PKD1 or PKD2 gene by germline and somatic mutations is necessary for cyst formation in ADPKD. To mechanistically understand cyst formation and growth, we isolated RCs from Korean patients with ADPKD and immortalized them with human telomerase reverse transcriptase (hTERT). Three hTERT-immortalized RC cell lines were characterized as proximal epithelial cells with germline and somatic PKD1 mutations. Thus, we first established hTERT-immortalized proximal cyst cells with somatic PKD1 mutations. Through transcriptome sequencing and Gene Ontology (GO) analysis, we found that upregulated genes were related to cell division and that downregulated genes were related to cell differentiation. We wondered whether the upregulated gene for the chemokine CXCL12 is related to the mTOR signaling pathway in cyst growth in ADPKD. CXCL12 mRNA expression and secretion were increased in RC cell lines. We then examined CXCL12 levels in RC fluids from patients with ADPKD and found increased CXCL12 levels. The CXCL12 receptor CXC chemokine receptor 4 (CXCR4) was upregulated, and the mTOR signaling pathway, which is downstream of the CXCL12/CXCR4 axis, was activated in ADPKD kidney tissue. To confirm activation of the mTOR signaling pathway by CXCL12 via CXCR4, we treated the RC cell lines with recombinant CXCL12 and the CXCR4 antagonist AMD3100; CXCL12 induced the mTOR signaling pathway, but the CXCR4 antagonist AMD3100 blocked the mTOR signaling pathway. Taken together, these results suggest that enhanced CXCL12 in RC fluids activates the mTOR signaling pathway via CXCR4 in ADPKD cyst growth.

Keywords

References

  1. Peters DJ and Breuning MH (2001) Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 358, 1439-1444 https://doi.org/10.1016/S0140-6736(01)06531-X
  2. Harris PC and Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60, 321-337 https://doi.org/10.1146/annurev.med.60.101707.125712
  3. Ghata J and Cowley BD Jr (2017) Polycystic Kidney Disease. Compr Physiol 7, 945-975 https://doi.org/10.1002/cphy.c160018
  4. Sutters M and Germino GG (2003) Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med 141, 91-101 https://doi.org/10.1067/mlc.2003.13
  5. Watnick TJ, Piontek KB, Cordal TM et al (1997) An unusual pattern of mutation in the duplicated portion of PKD1 is revealed by use of a novel strategy for mutation detection. Hum Mol Genet 6, 1473-1481 https://doi.org/10.1093/hmg/6.9.1473
  6. Rossetti S, Hopp K, Sikkink RA et al (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23, 915-933 https://doi.org/10.1681/ASN.2011101032
  7. Pei Y (2001) A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 7, 151-156 https://doi.org/10.1016/S1471-4914(01)01953-0
  8. Bodnar AG, Ouellette M, Frolkis M et al (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352 https://doi.org/10.1126/science.279.5349.349
  9. Counter CM, Hahn WC, Wei W et al (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95, 14723-14728 https://doi.org/10.1073/pnas.95.25.14723
  10. Lee KM, Choi KH and Ouellette MM (2004) Use of exogenous hTERT to immortalize primary human cells. Cytotechnology 45, 33-38 https://doi.org/10.1007/10.1007/s10616-004-5123-3
  11. Ouellette MM, McDaniel LD, Wright WE, Shay JW and Schultz RA (2000) The establishment of telomeraseimmortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet 9, 403-411 https://doi.org/10.1093/hmg/9.3.403
  12. Hein J, Boichuk S, Wu J et al (2009) Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J Virol 83, 117-127 https://doi.org/10.1128/JVI.01515-08
  13. Shirozu M, Nakano T, Inazawa J et al (1995) Structure and chromosomal localization of the human stromal cellderived factor 1 (SDF1) gene. Genomics 28, 495-500 https://doi.org/10.1006/geno.1995.1180
  14. Nagasawa T (2014) CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med 92, 433-439 https://doi.org/10.1007/s00109-014-1123-8
  15. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C (2013) CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 19, 12-22 https://doi.org/10.1016/j.molmed.2012.10.004
  16. Liekens S, Schols D and Hatse S (2010) CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16, 3903-3920 https://doi.org/10.2174/138161210794455003
  17. Guyon A (2014) CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci 8, 65 https://doi.org/10.3389/fncel.2014.00065
  18. Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM and Raymond E (2014) Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6, 340-352
  19. Scala S (2015) Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment. Clin Cancer Res 21, 4278-4285 https://doi.org/10.1158/1078-0432.CCR-14-0914
  20. Herbert BS, Grimes BR, Xu WM et al (2013) A telomerase immortalized human proximal tubule cell line with a truncation mutation (Q4004X) in polycystin-1. PLoS One 8, e55191 https://doi.org/10.1371/journal.pone.0055191
  21. Tan YC, Blumenfeld JD, Anghel R et al (2009) Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease. Hum Mutat 30, 264-273 https://doi.org/10.1002/humu.20842
  22. Jo HS, Eum WS, Park EY et al (2017) Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. BMB Rep 50, 460-465 https://doi.org/10.5483/BMBRep.2017.50.9.090